Vibeke Hatorp

989 total citations
15 papers, 780 citations indexed

About

Vibeke Hatorp is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Pharmacology. According to data from OpenAlex, Vibeke Hatorp has authored 15 papers receiving a total of 780 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Pharmacology and 4 papers in Pharmacology. Recurrent topics in Vibeke Hatorp's work include Diabetes Treatment and Management (13 papers), Pharmacology and Obesity Treatment (7 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Vibeke Hatorp is often cited by papers focused on Diabetes Treatment and Management (13 papers), Pharmacology and Obesity Treatment (7 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Vibeke Hatorp collaborates with scholars based in Denmark, United States and Germany. Vibeke Hatorp's co-authors include Mikael S. Thomsen, Kristian T. Hansen, Jeppe Sturis, Paul Rolan, Milan Zdravković, Søren Erik Larsen, Henrik Agersø, Lisbeth Bjerring Jensen, Grethe Jakobsen and Poul Strange and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Clinical Pharmacology & Therapeutics.

In The Last Decade

Vibeke Hatorp

14 papers receiving 716 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vibeke Hatorp Denmark 12 510 239 194 193 182 15 780
Dan Howard United States 16 523 1.0× 237 1.0× 153 0.8× 105 0.5× 230 1.3× 24 891
Dong‐Ryul Sohn South Korea 15 98 0.2× 171 0.7× 181 0.9× 380 2.0× 224 1.2× 27 864
James B. Mangold United States 15 121 0.2× 172 0.7× 52 0.3× 206 1.1× 167 0.9× 26 645
S. Irie Japan 12 147 0.3× 88 0.4× 233 1.2× 234 1.2× 326 1.8× 17 819
HL Elliott United Kingdom 17 147 0.3× 186 0.8× 111 0.6× 105 0.5× 49 0.3× 57 876
Venkateswar Jarugula United States 15 149 0.3× 197 0.8× 61 0.3× 95 0.5× 156 0.9× 24 655
B. Almé Sweden 12 111 0.2× 187 0.8× 217 1.1× 177 0.9× 573 3.1× 15 1.0k
Andr J Scheen Belgium 8 461 0.9× 250 1.0× 119 0.6× 58 0.3× 46 0.3× 8 758
SoJeong Yi South Korea 18 100 0.2× 130 0.5× 68 0.4× 157 0.8× 110 0.6× 45 705

Countries citing papers authored by Vibeke Hatorp

Since Specialization
Citations

This map shows the geographic impact of Vibeke Hatorp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vibeke Hatorp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vibeke Hatorp more than expected).

Fields of papers citing papers by Vibeke Hatorp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vibeke Hatorp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vibeke Hatorp. The network helps show where Vibeke Hatorp may publish in the future.

Co-authorship network of co-authors of Vibeke Hatorp

This figure shows the co-authorship network connecting the top 25 collaborators of Vibeke Hatorp. A scholar is included among the top collaborators of Vibeke Hatorp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vibeke Hatorp. Vibeke Hatorp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Hatorp, Vibeke, Kristian T. Hansen, & Mikael S. Thomsen. (2003). Influence of Drugs Interacting with CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide. The Journal of Clinical Pharmacology. 43(6). 649–660. 75 indexed citations
3.
Hatorp, Vibeke, Kristian T. Hansen, & Mikael S. Thomsen. (2003). Influence of Drugs Interacting with CYP3A4 on the Pharmacokinetics, Pharmacodynamics, and Safety of the Prandial Glucose Regulator Repaglinide. The Journal of Clinical Pharmacology. 43(6). 649–660. 11 indexed citations
4.
Hatorp, Vibeke. (2002). Clinical Pharmacokinetics and Pharmacodynamics of Repaglinide. Clinical Pharmacokinetics. 41(7). 471–483. 118 indexed citations
5.
Jakobsen, Grethe, Søren Erik Larsen, Henrik Agersø, et al.. (2002). Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects. Diabetes Care. 25(8). 1398–1404. 237 indexed citations
6.
Hatorp, Vibeke, et al.. (2001). Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. European Journal of Clinical Pharmacology. 57(2). 147–152. 66 indexed citations
7.
Hatorp, Vibeke & Mikael S. Thomsen. (2000). Drug Interaction Studies with Repaglinide: Repaglinide on Digoxin or Theophylline Pharmacokinetics and Cimetidine on Repaglinide Pharmacokinetics. The Journal of Clinical Pharmacology. 40(2). 184–192. 13 indexed citations
8.
Hatorp, Vibeke, et al.. (2000). Single‐Dose Pharmacokinetics of Repaglinide in Subjects with Chronic Liver Disease. The Journal of Clinical Pharmacology. 40(2). 142–152. 38 indexed citations
9.
Hatorp, Vibeke, et al.. (1999). Pharmacokinetic Profiles of Repaglinide in Elderly Subjects With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 84(4). 1475–1478. 17 indexed citations
10.
Hatorp, Vibeke, et al.. (1999). Repaglinide pharmacokinetics in healthy young adult and elderly subjects. Clinical Therapeutics. 21(4). 702–710. 50 indexed citations
11.
Hatorp, Vibeke, Karin Kramer Nielsen, Kevin T. Hansen, et al.. (1999). Absorption, metabolism and excretion of a single oral dose of 14 C-repaglinide during repaglinide multiple dosing. European Journal of Clinical Pharmacology. 55(7). 521–525. 66 indexed citations
12.
Hatorp, Vibeke, et al.. (1999). Disposition of one dose of 14C-repaglinide during non-labeled repaglinide multiple dosing. Clinical Pharmacology & Therapeutics. 65(2). 187–187. 2 indexed citations
13.
Damsbo, P., et al.. (1999). Flexible prandial glucose regulation with repaglinide in patients with Type 2 diabetes. Diabetes Research and Clinical Practice. 45(1). 31–39. 29 indexed citations
14.
Hatorp, Vibeke, et al.. (1999). Repaglinide pharmacokinetics in healthy & chronic liver disease subjects. Clinical Pharmacology & Therapeutics. 65(2). 187–187. 1 indexed citations
15.
Hatorp, Vibeke, et al.. (1998). Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.. PubMed. 36(12). 636–41. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dan Howard Breakdown of academic impact, for papers by Dong‐Ryul Sohn Breakdown of academic impact, for papers by James B. Mangold Breakdown of academic impact, for papers by S. Irie Breakdown of academic impact, for papers by HL Elliott Breakdown of academic impact, for papers by Venkateswar Jarugula Breakdown of academic impact, for papers by B. Almé Breakdown of academic impact, for papers by Andr J Scheen Breakdown of academic impact, for papers by SoJeong Yi
Rankless by CCL
2026